Introduction
============

Human endogenous retroviruses are replication-defective proviruses comprising a portion of human genome (∼8%). HERVs are recognized as having a role in health maintenance ([@B73]) and complex diseases ([@B69]; [@B52]; [@B30]) acting by remodeling structure and function of DNA. Although most of the HERV sequences have been inactivated over time, some of them remain active and, with LTRs, retain the genes encoding the structure, replication, and accessory proteins of retroviruses ([@B78]). LTRs contain regulatory sequences and their activity essentially depends on the chromatin and CpG island methylation of their regulatory regions ([@B39]). In different cell types and stages of development, HERV expression is mainly regulated by epigenetic mechanisms and is subjected to regulation according to the surrounding microenvironment ([@B35]). Numerous endogenous/exogenous factors lead to the activation of HERVs, including hormones ([@B11]), cytokines ([@B49]), cytotoxic chemicals/drugs ([@B21]; [@B51]), radiation ([@B63]), vitamins ([@B48]), and interactions with microorganisms ([@B5]; [@B71]; [@B29]).

In the last few decades, many studies have highlighted the involvement of HERVs in complex diseases, such as cancer, autoimmunity and neurological disorders ([@B80]; [@B52]). Although the research activity focused on the "omics" characterization of tumor from the primary site to the metastasis, the molecules that act as intermediaries between the epigenetic effect mediated by the microenvironment and cell fate haven't been completely identified.

The ability of tumors to adapt to microenvironmental changes is embedded in their plasticity. Moreover, on the basis of the genetic predisposition, both differentiated and stem cells are driven toward transformation by the epigenetic pressure of the tumor niche and the microenvironmental changes ([@B72]; [@B70]).

An overview of the knowledge on HERVs related to tumors, in light of our experience in melanoma, is provided in order to achieve new insights into the contribution of HERV-K to the crosstalk between cancer cells and the tumor microenvironment. In addition, we suggest future perspectives on their potential therapeutic uses.

Hervs in Cancer
===============

Several mechanisms by which HERVs could produce pathological effects have been proposed, including generation of new variants of HERVs, insertional mutagenesis, and protein toxicity ([@B80]). In this regard, HERV activation appears to influence the aggressiveness of different cancers, including seminoma, melanoma, leukemia, hepatocellular carcinoma, sarcoma, prostate, breast and colon cancer ([@B15]; [@B37]; [@B55]; [@B69]; [@B28]). Likewise, the pathologic process of rheumatic disorders, systemic lupus erythematosus, multiple sclerosis, autism spectrum disorders, schizophrenia, bipolar disorder, psoriasis, type I diabetes, and systemic sclerosis shows a correlation with HERV activity ([@B1]; [@B6]; [@B9]).

Several studies suggested that the aberrant activation of HERVs promotes tumorigenesis through oncogenic mechanisms, such as: (1) insertional mutagenesis with inactivation of tumor suppressor genes ([@B27]); (2) activation of downstream (proto-)oncogenes or genes involved in cell growth ([@B25]); (3) expression of HERV-K oncogenes such as Rec and Np9 ([@B20]; [@B16]); (4) expression of HERV proteins involved in the fusion of tumor cells or immunosuppression ([@B22]); (5) disruption of cellular checkpoints ([@B38]; [@B46]).

Manifold HERV families have been identified; the HERV-K family is the most recently integrated in human genome, comprising 10 so-called HML subgroups ([@B68]). Of these, HML-2 subgroup maintains most of the ORFs actively transcribed. Due to differential transcript splicing and the deletion of 292-bp at the *pol* and *env* boundary, HML-2 produces the protein Env (single spliced) and accessory proteins Np9 and Rec (double spliced) ([@B4]; [@B10]). Their identification helped to understand and characterize this subgroup of HERV-K in many tumors, including ovarian, breast and prostate cancer, melanoma, lymphomas, leukemias, and sarcomas ([@B15]; [@B37]). HERV-K DNA-polymorphisms, mRNA and proteins have been detected in cancer cells; in addition, viral particles have been identified in tissue, serum, and cell lines ([@B33]). Interestingly, HERV-K is involved in cell transformation and contributes to the metastatic phenotype ([@B22]). Accordingly, we demonstrated the reactivation of HERV-K under restrictive conditions to be strictly required in human melanoma cells to support the expansion of a subpopulation of cancer cells with stemness features ([@B64]; [@B3]).

Hervs and Stemness
==================

Stem cells have self-renewal capacity and give rise to progeny capable of differentiating into diverse cell types. The transcription factors OCT4, SOX2, and NANOG have fundamental roles in maintaining the pluripotency and stemness features of hESCs and contribute to the reprogramming of adult somatic cells into iPSCs ([@B36]; [@B79]). Recent studies showed HERV activity (mainly HERV-H and HERV-K) in hESCs and iPSC ([@B53]; [@B31]). Specifically, LTR7/HERV-H is one of the transposable elements found more often at the binding sites of OCT4 and NANOG ([@B44]) and its targeting compromises the self-renewal functions ([@B74]). Furthermore, DNA hypomethylation at HERV-K LTRs elements together with transactivation by OCT4, increase HERV-K expression during embryogenesis. In addition, the overexpression of Rec in pluripotent cells increases the interferon-induced transmembrane protein 1 (IFITM1), suggesting a role of HERV-K in the immunoprotection of human embryos against viruses sensitive to the IFITM1-type restriction ([@B31]).

Possessing stemness features is crucial for cancer progression and metastasis. The generation of subpopulations with stemness features determines cancer self-renewal, proliferation and differentiation, allowing immune evasion and acquisition of resistance to therapy. These subpopulations, called CSCs, give rise to heterogeneous cell populations and maintain an undifferentiated state that equips them with the plasticity required to survive environmental stress ([@B2]; [@B57]).

The role of HERVs in stemness and the acquisition of cancer stemness are linked by a complex crosstalk of cellular signals, in which microenvironmental changes play a significant role ([@B12]; [@B3]; [@B26]).

The Role of HERV-K in the Plasticity of Cancer Cells: Our Point of View in Melanoma
===================================================================================

Several studies suggest that the tumorigenesis is determined by genetic alterations, which contribute to transformation, as well as by external factors present in the cancer microenvironment. The microenvironment is therefore considered a part of the tumor that constantly changes in parallel with cancer progression, as a result of bidirectional interactions between tumor cells and cellular and molecular components of their "niche" ([@B56]; [@B75]). These interactions are essential for the establishment of a permissive stem cell microenvironment, providing a fine balance between self-renewal/differentiation and quiescence/proliferation. The tumor microenvironment is characterized by adverse growth conditions (hypoxia and acidosis), which trigger a stress response in cancer cells that, with molecules such as cytokines and growth factors, is instrumental in phenotype switching, angiogenesis, tumor growth, and immune evasion.

Cellular plasticity is fundamental for tumor progression and metastasis, to adapt to changes in the microenvironment ([@B70]). Aggressive cancer cells share many characteristics with embryonal progenitors, expressing developmental genes that allow the differentiation into a wide range of cell lineages, including neural, mesenchymal, and endothelial cells. This mimicry of other cell lineages becomes essential in the cancer's ability to adapt to microenvironmental changes. For instance, melanoma cells show phenotypic heterogeneity and maintain their morphological and biological plasticity despite repeated cloning ([@B8]; [@B32]; [@B7]).

Several studies from our and other groups demonstrated that HERV-K (HML-2), has a potential aggravating role in malignant melanoma and in immune escape during metastasis ([@B10]; [@B64]; [@B3]). Since HERV-K is responsive to microenvironmental changes, and melanoma cells are strongly associated with epigenetic and microenvironmental anomalies, the association of HERV-K activation with carcinogenesis is particularly intriguing ([@B47]; [@B60]).

Our group has established and characterized a metastatic human melanoma cell line, termed TVM-A12, that is highly heterogeneous, plastic and responds strongly to microenvironmental alterations ([@B50]; [@B64]; [@B3]) (**Figure [1](#F1){ref-type="fig"}**). This has supplied a model to study the crosstalk between HERVs and cancer cells in a changing microenvironment. The TVM-A12 cellular monolayer is characterized by the presence of cells with different morphologies including small ovoid, spindle polygonal and large dendritic forms. Notably, the multiple morphology with melanin production persisted after years of continued passage in culture. When grown in different media, despite changing the morphology and functional characteristics, TVM-A12 retain the ability to restore the original phenotype if standard conditions are re-established. Peculiarly, when cultured in specific media that promote differentiation, TVM-A12 cells show specific phenotypes of melanogenic, adipogenic, and osteogenic lineages (unpublished data) (**Figure [1](#F1){ref-type="fig"}**). This morphological transition correlated with the change of culture media, without committing to terminal differentiation, has been previously described and is considered a hallmark of stemness in melanoma cells ([@B82]).

![HERV-K as the master of melanoma plasticity in tumor adaptation to microenvironment. In response to different types of media, TVM-A12 melanoma cells change morphology and functional properties. The acquisition of undifferentiated and of stemness features under microenvironment alterations is HERV-K-dependent and related to increased malignancy, metastatic potential, and immune evasion.](fmicb-09-01448-g001){#F1}

TVM-A12 cells were also cultured at low serum concentrations (RPMI with 1%FBS), a recognized protocol for inducing microenvironmental stress conditions *in vitro*. This prompted a change in their phenotype, switching from adherent to suspension cells, generating a highly proliferating cell line called Clone6 (**Figure [1](#F1){ref-type="fig"}**). A major event for the generation of metastatic tumor cells is the inhibition of anoikis, the programmed cell death pathway induced by loss of integrin-mediated cell matrix interactions, revealed *in vitro* by the ability of cells to grow in an anchorage-independent manner ([@B54]). In the case of Clone6, following cell detachment, cells undergo uncontrolled growth and show loss of expression of immune recognition molecules (MHC-I, Melan A/MART-1), loss of melanin production and ability to generate tumor masses in mice (unpublished data), as one would expect from highly malignant cells. Uniquely, Clone6 cells are unable to return to the original phenotype when standard culture conditions are re-established, and there is a marked transcriptional activation of HERV-K with the concomitant production and release of viral particles, along with these phenotypic and functional changes. The generation of Clone6 from TVM-A12 is shown to be dependent on HERV-K as down-regulation by RNA interference prevents it.

When switching to a serum free medium, such as X-VIVO (typically used for stem cells), TVM-A12 generated non-adherent dark cellular aggregates called Grapes, with a low growth rate (**Figure [1](#F1){ref-type="fig"}**). Grapes are characterized by increased expression of CSCs markers (CD133 and nestin), loss of expression of immune recognition molecules (MHC-I, Melan A/MART-1) and an increase in melanoma progression and metastasis associated markers (CD10 and CXCR4). This phenotype switch is accompanied by an increased expression of HERV-K, and the link to microenvironmental changes is confirmed by a strong down-regulation of HERV-K expression when cells are returned to media containing serum (RPMI with 10%FBS; X-VIVO with 2--10%FBS). Once again confirming its important role, the silencing of HERV-K in TVM-A12 leads to a reduction in Grapes formation and an induction of cell death.

This HERV-K interference, during Grapes generation, also specifically inhibits the expansion of a CD133+ subpopulation with stemness features, demonstrating the requirement of HERV-K activation to sustain the expansion of this subpopulation. Microenvironmental stress is indicated as critical for regulating stemness of tumor cells ([@B56]). This subpopulation is characterized by recognized hallmarks of cancer aggressiveness such as high expression of OCT4, self-renewing, migration and invasion capacity. Remarkably, when these cells are treated with NNRTIs such as efavirenz and nevirapine, the results mimic HERV-K interference, with a decrease in HERV-K expression and a concomitant cell death induction. We cannot be certain if the effect of NNRTIs treatment is due to a direct inhibition of the reverse transcriptase of HERV-K or is mediated by the action on other cellular components such as LINE-1 ([@B65]).

Tumors are graded and evaluated based on their degree of cellular differentiation, more malignant cancers lose the characteristics of the original tissue and approach a more stem-cell-like state ([@B45]). Given this, it appears that HERV-K inhibition offers a promising avenue of research for combination therapy in cancer.

HERV-K and the Acquisition of Cancer Hallmarks: Rationale for Combination Therapies
===================================================================================

Cell heterogeneity and plasticity are the main drivers of the clonal evolution of genetic resistance and the emergence of highly metastatic tumor phenotypes resistant to conventional chemotherapies and radiation ([@B66]; [@B60]). The phenotype-switching ability of melanoma cells in response to the microenvironment drives the dynamicity of its immune escape and malignant characteristics ([@B47]). Accordingly, our studies on melanoma have shown how the activation of HERV-K under microenvironmental stress induces and maintains tumor cell plasticity and determines the acquisition of the typical cancer hallmarks, such as changes in phenotype, stemness feature, immune evasion, and metastasis (**Figure [2A](#F2){ref-type="fig"}**). Cancer progression is accompanied by metabolic alterations and epigenetic reprogramming. The tumor microenvironment, poor in nutrients and oxygen, is responsible for the metabolic switch observed in cancer cells. The accumulation of glycolysis metabolic products, such as lactate, induces local immune suppression, which facilitates tumor progression and metastasis ([@B59]). Both cellular nutrient metabolism and chromatin organization are remodeled in cancer cells, and these alterations play a key role in tumor development and growth. Indeed, many chromatin modifying-enzymes utilize metabolic intermediates as cofactors or substrates, and recent studies have shown that the epigenome is sensitive to cellular metabolism ([@B81]). Thus, while epigenetic alterations can modify the expression of metabolic enzymes, the metabolic reprogramming can affect the cancer cell epigenome as well (by DNA methylation and histone modifications). One of the most important events for the development and progression of cancer is global DNA hypomethylation ([@B24]; [@B62]); indeed, the expression of HERV-K is strongly associated with hypomethylation ([@B67]; [@B42]), and with increased genomic instability and transcriptome activity ([@B61]). In this context, the identification and study of mechanisms and regulators of the metabolic switch and epigenetic modifiers, with an eye toward targeted therapies to be used in combination, should provide more effective cancer therapies.

![HERV-K provides new avenues for combination therapy. **(A)** HERV-K and cancer hallmarks. In melanoma cells, microenvironment modifications lead to the increase of HERV-K transcriptional activity associated to cell plasticity and different hallmarks of cancer such as phenotype switching, stemness features, immune evasion, and metastatic properties. **(B)** HERV-K targeting in cancer combination therapy. Targeting HERV-K in association with conventional and innovative therapies such as immunotherapy, cell transdifferentiation/reprogramming-inducing agents, epigenetic modifiers and antiretrovirals, could shift the balance in the search for effective and less toxic cancer treatment.](fmicb-09-01448-g002){#F2}

The eradication of tumors and prevention of recurrences are current challenges in cancer therapy. Thus, starting from conventional cancer treatments, including chemotherapy, radiotherapy and surgery, new combination approaches are needed. In this view, we consider HERV-K targeting as a strategy to improve response to therapy (**Figure [2B](#F2){ref-type="fig"}**). The enhancement of patient's immune response plays a key role in the treatment of cancer. Indeed, in the field of cancer immunotherapy, progress has been made in the development of new technologies aimed at boosting the immune system, such as monoclonal antibodies and engineered CAR-T against tumor antigens ([@B40]). Actually, targeting of the HERV-K envelope protein by CAR-T cells has already been reported as a potential immunotherapeutic approach for melanoma and other tumors ([@B43]). Targeted immunotherapy research demonstrated the potential of anti-HML-2-Env antibodies in inhibiting tumor growth and inducing apoptosis, both *in vitro* and *in vivo* mouse models ([@B76]). Moreover, based on the immunogenic property of HERV-K proteins ([@B58]), studies are underway on a peptide-based vaccine derived from HERV-K in order to control the spread of cancer ([@B41]).

Another approach is the identification of the microenvironmental factors and the corresponding signal transduction pathways that are responsible for transdifferentiation of cancer cells. These could be potential targets for a new therapeutic approach for cancer reprogramming into a differentiated state, with a decrease or even loss of cancer stemness features and malignancy ([@B14]). One promising result in this direction has been the achievement of a new type of cancer cell reprogramming: the osteogenic differentiation of neuroblastoma cells, switched to a different germ layer through rapamycin induction in the presence of a scaffold, without an intermediate iPSCs step ([@B13]). It would be of interest to study how the expression of retroelements is regulated during the cancer transdifferentiation process.

Histone deacetylate inhibitors are currently used in the clinical setting as anticancer agents that alter the regulation of histone proteins. HDACi can modify the acetylation status of histones, resulting in the induction of cell cycle arrest, apoptosis or differentiation ([@B23]). HDACi potentially re-activate HERVs, however, the beneficial or detrimental effects of epigenetic drugs on HERV modulation are currently discussed ([@B17]; [@B34]; [@B19]; [@B77]).

In a broader context, our group and other authors had already suggested intervening on the activity of retroelements with antiretroviral drugs ([@B65]; [@B3]; [@B18]), which now more than ever appears as a promising new component in future combination therapies in cancer.

Future Directions
=================

In this scenario, the responsiveness to external stimuli of HERVs attributes to these genetic elements a high relevance in the crosstalk between tumor and microenvironment. Based on our experience we have demonstrated that HERV-K is fundamental in the acquisition of stemness features and aggressiveness under the pressure of the microenvironment. Following the path indicated by our results on melanoma cells, we aim to widen the scope and depth of our knowledge of HERV-K in cancer plasticity, by exploring other cancer types and by deciphering the molecular pathways underlying the responsiveness of HERV-K to the microenvironment. We believe that future combination therapies able to target HERV-K and other retroelements will become indispensable weapons in a wider arsenal for fighting cancers. Therefore, we propose that expanding the range of therapeutic options will allow defining personalized combination therapies in the future.
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FBS
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:   human embryonic stem cells
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:   long terminal repeats
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NANOG

:   DNA binding homeobox transcription factor
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